RESUMO
BACKGROUND: Metastatic breast cancer (MBC) and the circulating tumor cells (CTCs) leading to macrometastases are inherently different than primary breast cancer. We evaluated whether whole transcriptome RNA-Seq of CTCs isolated via an epitope-independent approach may serve as a surrogate for biopsies of macrometastases. METHODS: We performed RNA-Seq on fresh metastatic tumor biopsies, CTCs, and peripheral blood (PB) from 19 newly diagnosed MBC patients. CTCs were harvested using the ANGLE Parsortix microfluidics system to isolate cells based on size and deformability, independent of a priori knowledge of cell surface marker expression. RESULTS: Gene expression separated CTCs, metastatic biopsies, and PB into distinct groups despite heterogeneity between patients and sample types. CTCs showed higher expression of immune oncology targets compared with corresponding metastases and PB. Predictive biomarker (n = 64) expression was highly concordant for CTCs and metastases. Repeat observation data post-treatment demonstrated changes in the activation of different biological pathways. Somatic single nucleotide variant analysis showed increasing mutational complexity over time. CONCLUSION: We demonstrate that RNA-Seq of CTCs could serve as a surrogate biomarker for breast cancer macrometastasis and yield clinically relevant insights into disease biology and clinically actionable targets.
Assuntos
Neoplasias da Mama , Células Neoplásicas Circulantes , Biomarcadores Tumorais/metabolismo , Biópsia , Neoplasias da Mama/patologia , Feminino , Humanos , Metástase Neoplásica , Células Neoplásicas Circulantes/patologia , TranscriptomaRESUMO
BACKGROUND: Individualising treatment in breast cancer requires effective predictive biomarkers. While relatively few genomic aberrations are clinically relevant, there is a need for characterising patients across different subtypes to identify actionable alterations. METHODS: We identified genomic alterations in 49 potentially actionable genes for which drugs are available either clinically or via clinical trials. We explored the landscape of mutations and copy number alterations (CNAs) in actionable genes in seven breast cancer subtypes utilising The Cancer Genome Atlas. To dissect the genomic complexity, we analysed the patterns of co-occurrence and mutual exclusivity in actionable genes. RESULTS: We found that >30% of tumours harboured putative actionable events that are targetable by currently available drugs. We identified genes that had multiple targetable alterations, representing candidate targets for combination therapy. Genes predicted to be drivers in primary breast tumours fell into five categories: mTOR pathway, immune checkpoints, oestrogen signalling, tumour suppression and DNA damage repair. Our analysis also revealed that CNAs in 34/49 (69%) and mutations in 13/49 (26%) genes were significantly associated with gene expression, validating copy number events as a dominant oncogenic mechanism in breast cancer. CONCLUSION: These results may enable the acceleration of personalised therapy and improve clinical outcomes in breast cancer.
Assuntos
Neoplasias da Mama/genética , Variações do Número de Cópias de DNA , Redes Reguladoras de Genes , Mutação , Adulto , Idoso , Idoso de 80 Anos ou mais , Bases de Dados Genéticas , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Pessoa de Meia-Idade , Medicina de Precisão , Análise de Sequência de RNA , Sequenciamento do ExomaRESUMO
The comparison of the landscape of somatic alterations in circulating tumor cells (CTCs) versus metastases is challenging. Here, we comprehensively characterized the somatic landscape in bulk (amplified and non-amplified), spike-in breast cancer cells, CTCs, and metastases from breast cancer patients using whole-exome sequencing (WES). We determined the level of genomic concordance for somatic nucleotide variants (SNVs), copy number alterations (CNAs), and structural variants (SVs). The variant allele fractions (VAFs) of somatic variants were remarkably similar between amplified and non-amplified cell line samples as technical replicates. In clinical samples, a significant fraction of somatic variants had low VAFs in CTCs compared to metastases. The most frequently recurrent gene mutations in clinical samples were associated with an elevated C > T mutational signature. We found complex rearrangement patterns including intra- and inter-chromosomal rearrangements, singleton, and recurrent gene fusions, and tandem duplications. We observed high molecular discordance for somatic alterations between paired samples consistent with marked heterogeneity of the somatic landscape. The most prevalent copy number calls were focal deletion events in CTCs and metastases. Our results demonstrate the feasibility of an integrated workflow for the identification of a complete repertoire of somatic alterations and highlight the intrapatient genomic differences that occur between CTCs and metastases.
Assuntos
Neoplasias da Mama/genética , Neoplasias da Mama/patologia , Exoma/genética , Metástase Neoplásica/genética , Células Neoplásicas Circulantes/patologia , Alelos , Biópsia , Linhagem Celular Tumoral , Variações do Número de Cópias de DNA/genética , Estudos de Viabilidade , Feminino , Humanos , Mutação/genética , Projetos Piloto , Sequenciamento do Exoma/métodosRESUMO
BACKGROUND: We characterized the whole transcriptome of circulating tumor cells (CTCs) in stage II-III breast cancer to evaluate correlations with primary tumor biology. METHODS: CTCs were isolated from peripheral blood (PB) via immunomagnetic enrichment followed by fluorescence-activated cell sorting (IE/FACS). CTCs, PB, and fresh tumors were profiled using RNA-seq. Formalin-fixed, paraffin-embedded (FFPE) tumors were subjected to RNA-seq and NanoString PAM50 assays with risk of recurrence (ROR) scores. RESULTS: CTCs were detected in 29/33 (88%) patients. We selected 21 cases to attempt RNA-seq (median number of CTCs = 9). Sixteen CTC samples yielded results that passed quality-control metrics, and these samples had a median of 4,311,255 uniquely mapped reads (less than PB or tumors). Intrinsic subtype predicted by comparing estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) versus PAM50 for FFPE tumors was 85% concordant. However, CTC RNA-seq subtype assessed by the PAM50 classification genes was highly discordant, both with the subtype predicted by ER/PR/HER2 and by PAM50 tumors. Two patients died of metastatic disease, both of whom had high ROR scores and high CTC counts. We identified significant genes, canonical pathways, upstream regulators, and molecular interaction networks comparing CTCs by various clinical factors. We also identified a 75-gene signature with highest expression in CTCs and tumors taken together that was prognostic in The Cancer Genome Atlas and Molecular Taxonomy of Breast Cancer International Consortium datasets. CONCLUSION: It is feasible to use RNA-seq of CTCs in non-metastatic patients to discover novel tumor biology characteristics.
Assuntos
Biomarcadores Tumorais/genética , Neoplasias da Mama/genética , Neoplasias da Mama/patologia , Sequenciamento de Nucleotídeos em Larga Escala/métodos , Células Neoplásicas Circulantes/metabolismo , Células Neoplásicas Circulantes/patologia , RNA Neoplásico/genética , Estudos de Viabilidade , Feminino , Seguimentos , Humanos , Separação Imunomagnética , Estadiamento de Neoplasias , Projetos Piloto , Prognóstico , Estudos Prospectivos , Taxa de SobrevidaRESUMO
Herpes simplex virus (HSV) was originally implicated in the aetiology of cervical cancer, and although high-risk human papillomavirus (HPV) is now the accepted causative agent, the epidemiological link between HSV and HPV-associated cancers persists. The annexin A2 heterotetramer (A2t) has been shown to mediate infectious HPV type 16 (HPV16) uptake by human keratinocytes, and secretory leukocyte protease inhibitor (SLPI), an endogenous A2t ligand, inhibits HPV16 uptake and infection. Interestingly, HSV infection induces a sustained downregulation of SLPI in epithelial cells, which we hypothesized promotes HPV16 infection through A2t. Here, we show that in vitro infection of human keratinocytes with HSV-1 or HSV-2, but not with an HSV-1 ICP4 deletion mutant that does not downregulate SLPI, leads to a >70% reduction of SLPI mRNA and a >60% decrease in secreted SLPI protein. Consequently, we observed a significant increase in the uptake of HPV16 virus-like particles and gene transduction by HPV16 pseudovirions (two- and 2.5-fold, respectively) in HSV-1- and HSV-2-infected human keratinocyte cell cultures compared with uninfected cells, whereas exogenously added SLPI reversed this effect. Using a SiMPull (single-molecule pulldown) assay, we demonstrated that endogenously secreted SLPI interacts with A2t on epithelial cells in an autocrine/paracrine manner. These results suggested that ongoing HSV infection and resultant downregulation of local levels of SLPI may impart a greater susceptibility for keratinocytes to HPV16 infection through the host cell receptor A2t, providing a mechanism that may, in part, provide an explanation for the aetiological link between HSV and HPV-associated cancers.
Assuntos
Interações Hospedeiro-Patógeno , Papillomavirus Humano 16/fisiologia , Queratinócitos/virologia , Inibidor Secretado de Peptidases Leucocitárias/metabolismo , Simplexvirus/fisiologia , Internalização do Vírus , Linhagem Celular , Regulação para Baixo , HumanosRESUMO
BACKGROUND: LIGHT, a ligand for lymphotoxin-ß receptor (LTßR) and herpes virus entry mediator, is predominantly expressed on activated immune cells and LTßR signaling leads to the recruitment of lymphocytes. The interaction between LIGHT and LTßR has been previously shown to activate immune cells and result in tumor regression in a virally-induced tumor model, but the role of LIGHT in tumor immunosuppression or in a prostate cancer setting, where self antigens exist, has not been explored. We hypothesized that forced expression of LIGHT in prostate tumors would shift the pattern of immune cell infiltration toward an anti-tumoral milieu, would inhibit T regulatory cells (Tregs) and would induce prostate cancer tumor associated antigen (TAA) specific T cells that would eradicate tumors. METHODS: Real Time PCR was used to evaluate expression of forced LIGHT and other immunoregulatory genes in prostate tumors samples. For in vivo studies, adenovirus encoding murine LIGHT was injected intratumorally into TRAMP-C2 prostate cancer cell tumor bearing mice. Chemokine and cytokine concentrations were determined by multiplex ELISA. Flow cytometry was used to phenotype tumor infiltrating lymphocytes and expression of LIGHT on the tumor cell surface. Tumor-specific lymphocytes were quantified via ELISpot assay. Treg induction and Treg suppression assays determined Treg functionality after LIGHT treatment. RESULTS: LIGHT in combination with a therapeutic vaccine, PSCA TriVax, reduced tumor burden. LIGHT expression peaked within 48 hr of infection, recruited effector T cells that recognized mouse prostate stem cell antigen (PSCA) into the tumor microenvironment, and inhibited infiltration of Tregs. Tregs isolated from tumor draining lymph nodes had impaired suppressive capability after LIGHT treatment. CONCLUSION: Forced LIGHT treatment combined with PSCA TriVax therapeutic vaccination delays prostate cancer progression in mice by recruiting effector T lymphocytes to the tumor and inhibiting Treg mediated immunosuppression. Prostate 75:280-291, 2015. © 2014 Wiley Periodicals, Inc.
Assuntos
Vacinas Anticâncer/imunologia , Próstata/metabolismo , Neoplasias da Próstata/metabolismo , Linfócitos T Reguladores/imunologia , Membro 14 da Superfamília de Ligantes de Fatores de Necrose Tumoral/metabolismo , Animais , Tolerância Imunológica , Terapia de Imunossupressão , Masculino , Camundongos , Próstata/imunologia , Próstata/patologia , Neoplasias da Próstata/imunologia , Neoplasias da Próstata/patologia , Linfócitos T Reguladores/metabolismo , Membro 14 da Superfamília de Ligantes de Fatores de Necrose Tumoral/genéticaRESUMO
Triple-negative breast cancer (TNBC) is characterized by an aggressive clinical presentation and a paucity of clinically actionable genomic alterations. Here, we utilized the Cancer Genome Atlas (TCGA) to explore the proteogenomic landscape of TNBC subtypes to see whether genomic alterations can be inferred from proteomic data. We found only 4% of the protein level changes are explained by mutations, while 21% of the protein and 35% of the transcriptomics changes were determined by copy number alterations (CNAs). We found tighter coupling between proteome and genome in some genes that are predicted to be the targets of drug inhibitors, including CDKs, PI3K, tyrosine kinase (TKI), and mTOR. The validation of our proteogenomic workflow using mass spectrometry Clinical Proteomic Tumor Analysis Consortium (MS-CPTAC) data also demonstrated the highest correlation between protein-RNA-CNA. The integrated proteogenomic approach helps to prioritize potentially actionable targets and may enable the acceleration of personalized cancer treatment.
RESUMO
Neuroblastoma is the most common extracranial solid tumor of childhood. While MYCN and mutant anaplastic lymphoma kinase (ALKF1174L) cooperate in tumorigenesis, how ALK contributes to tumor formation remains unclear. Here, we used a human stem cell-based model of neuroblastoma. Mis-expression of ALKF1174L and MYCN resulted in shorter latency compared to MYCN alone. MYCN tumors resembled adrenergic, while ALK/MYCN tumors resembled mesenchymal, neuroblastoma. Transcriptomic analysis revealed enrichment in focal adhesion signaling, particularly the extracellular matrix genes POSTN and FN1 in ALK/MYCN tumors. Patients with ALK-mutant tumors similarly demonstrated elevated levels of POSTN and FN1. Knockdown of POSTN, but not FN1, delayed adhesion and suppressed proliferation of ALK/MYCN tumors. Furthermore, loss of POSTN reduced ALK-dependent activation of WNT signaling. Reciprocally, inhibition of the WNT pathway reduced expression of POSTN and growth of ALK/MYCN tumor cells. Thus, ALK drives neuroblastoma in part through a feedforward loop between POSTN and WNT signaling.
Assuntos
Neuroblastoma , Receptores Proteína Tirosina Quinases , Humanos , Quinase do Linfoma Anaplásico/genética , Moléculas de Adesão Celular , Linhagem Celular Tumoral , Proteína Proto-Oncogênica N-Myc/genética , Proteína Proto-Oncogênica N-Myc/metabolismo , Neuroblastoma/patologia , Receptores Proteína Tirosina Quinases/metabolismo , Via de Sinalização WntRESUMO
Tumor-associated macrophages (TAM) and cancer-associated fibroblasts (CAF) and their precursor mesenchymal stromal cells (MSC) are often detected together in tumors, but how they cooperate is not well understood. Here, we show that TAM and CAF are the most abundant nonmalignant cells and are present together in untreated human neuroblastoma (NB) tumors that are also poorly infiltrated with T and natural killer (NK) cells. We then show that MSC and CAF-MSC harvested from NB tumors protected human monocytes (MN) from spontaneous apoptosis in an interleukin (IL)-6 dependent mechanism. The interactions of MN and MSC with NB cells resulted in a significant induction or increase in the expression of several pro-tumorigenic cytokines/chemokines (TGF-ß1, MCP-1, IL-6, IL-8, and IL-4) but not of anti-tumorigenic cytokines (TNF-α, IL-12) by MN or MSC, while also inducing cytokine expression in quiescent NB cells. We then identified a TGF-ß1/IL-6 pathway where TGF-ß1 stimulated the expression of IL-6 in NB cells and MSC, promoting TAM survival. Evidence for the contribution of TAM and MSC to the activation of this pathway was then provided in xenotransplanted NB tumors and patients with primary tumors by demonstrating a direct correlation between the presence of CAF and p-SMAD2 and p-STAT3. The data highlight a new mechanism of interaction between TAM and CAF supporting their pro-tumorigenic function in cancer.
Assuntos
Fibroblastos , Interleucina-6 , Macrófagos , Neuroblastoma , Fator de Crescimento Transformador beta1 , Humanos , Neuroblastoma/imunologia , Fibroblastos/imunologia , Macrófagos/imunologia , AnimaisRESUMO
Whole exome sequencing (WES), targeted gene panel sequencing and single nucleotide polymorphism (SNP) arrays are increasingly used for the identification of actionable alterations that are critical to cancer care. Here, we compared The Cancer Genome Atlas (TCGA) and the Genomics Evidence Neoplasia Information Exchange (GENIE) breast cancer genomic datasets (array and next generation sequencing (NGS) data) in detecting genomic alterations in clinically relevant genes. We performed an in silico analysis to determine the concordance in the frequencies of actionable mutations and copy number alterations/aberrations (CNAs) in the two most common breast cancer histologies, invasive lobular and invasive ductal carcinoma. We found that targeted sequencing identified a larger number of mutational hotspots and clinically significant amplifications that would have been missed by WES and SNP arrays in many actionable genes such as PIK3CA, EGFR, AKT3, FGFR1, ERBB2, ERBB3 and ESR1. The striking differences between the number of mutational hotspots and CNAs generated from these platforms highlight a number of factors that should be considered in the interpretation of array and NGS-based genomic data for precision medicine. Targeted panel sequencing was preferable to WES to define the full spectrum of somatic mutations present in a tumor.
Assuntos
Neoplasias da Mama/genética , Bases de Dados Genéticas/normas , Bases de Dados Genéticas/tendências , Neoplasias da Mama/patologia , Simulação por Computador , Variações do Número de Cópias de DNA/genética , Exoma/genética , Feminino , Genômica/métodos , Sequenciamento de Nucleotídeos em Larga Escala/métodos , Humanos , Mutação/genética , Medicina de Precisão/métodosRESUMO
Circulating tumor cells (CTCs) have potential utility as a surrogate biomarker of tumor biology via a liquid biopsy. The aim of this study was to evaluate if the nCounter NanoString assay could be used for accurate gene expression profiling of CTCs using the PAM50 research-use-only CodeSet. Analysis was performed on CTCs isolated by the ANGLE Parsortix system from healthy blood spiked with the breast cancer cell lines Hs578T, SkBr3, MDA-MB-231 or MCF7. Using cell lines as gold standard positive controls and Parsortix processed blood without spiking (unspiked) as negative controls, we found an average of 12 significantly differentially expressed genes among spiked samples versus unspiked controls. We validated our findings with the NanoStringDiff differential expression statistical method. The NanoString recommended targeted pre-amplification introduced false positive results due to pre-amplification bias, and the amplification of non-cancer genes from normal leukocytes confounded gene expression profiling of CTCs. Pre-amplification bias is a concern for other similar assays that may be used as discovery tools or target validation of transcripts of interest in gene expression profiling of CTCs. We recommend the use of an unspiked negative control when evaluating CTC technologies regarding gene expression profiling. Given that the molecular profiling of CTCs as a liquid biopsy may have clinical ramifications for potential treatment selection in future clinical trials, our study emphasizes cautious consideration of pre-analytical variables such as amplification bias in the context of liquid biopsy studies.
RESUMO
The identification of mycobacterial species in clinical isolates is essential for making patient care decisions. Polymerase chain reaction (PCR) restriction enzyme analysis (PRA) is a simple and rapid identification method, based on amplification of 441 bp of the hsp65 gene and restriction with BstEII and HaeIII. As a contribution to the validation of PRA, a multicenter study was performed in eight laboratories located in Argentina, Brazil, Colombia, Chile, and Guadeloupe. Each laboratory received 18 coded isolates from the collection of the Institute of Tropical Medicine (Antwerp, Belgium), representing duplicates of nine laboratory strains: Mycobacterium terrae CIPT 140320001, Mycobacterium scrofulaceum CIPT 140220031, Mycobacterium flavescens ATCC 14474, Mycobacterium triviale ATCC 23292, Mycobacterium nonchromogenicum ATCC 19530, Mycobacterium chitae ATCC 19627, Mycobacterium abscessus ATCC 19977, Mycobacterium kansasii ATCC 12478, and Mycobacterium peregrinum ATCC 14467. A detailed protocol including amplification, enzymatic digestion, and gel preparation was provided to each laboratory. Two laboratories identified correctly all 18 (100%) isolates, one identified correctly 17 (94.5%), two identified 14 (77.7%), one identified 11 (61%), and two identified 8 (44.4%) isolates. Errors detected in laboratories with more than 77% accuracy were associated with electrophoresis running conditions and an unspecific amplicon produced by a single strain. Lower accuracy was mainly related to inappropriate use of DNA markers and insufficient training in interpretation of patterns. In conclusion, the PRA method was readily implemented in some Latin American and Caribbean laboratories of mycobacteria, but improvements in critical points, as gel running conditions and training in interpretiation of patterns, are needed in order to improve accuracy. In others, improvement in critical points is still necessary.
Assuntos
Infecções por Mycobacterium/diagnóstico , Mycobacterium/isolamento & purificação , Reação em Cadeia da Polimerase/métodos , Proteínas de Bactérias/química , Proteínas de Bactérias/genética , Chaperonina 60 , Chaperoninas/química , Chaperoninas/genética , DNA Bacteriano/química , DNA Bacteriano/genética , Guadalupe , Humanos , Mycobacterium/genética , Reação em Cadeia da Polimerase/normas , Mapeamento por Restrição , América do SulRESUMO
BACKGROUND: Expeditious charactization of drug susceptibility in Mycobacterium tuberculosis is difficult and, calls for the design and evaluation of faster, cheaper and more effective new techniques. OBJECTIVE: The aim of the current study was to compare one genotypic and two phenotypic methods for rapid susceptibility detection of M. tuberculosis. MATERIAL AND METHODS: Twenty-one M. tuberculosis strains were evaluated by phenotypic methodologies of oxidation and reduction of Alamar blue and MTT in the presence of streptomycin, isoniazid, rifampin and ethambutol. In all tests, the proportion method was applied as the comparison standard. By means of receiver operative characteristic (ROC) analysis, the performance, predictive values and threshold values for all drugs were determined. In addition, the performance of PCR and reverse line blot hybridization in establishing predictive values for sensitivity and resistance were compared in contingency tables. RESULTS: The susceptibility patterns established by colorimetric techniques were obtained after seven days of incubation. The performances of these tests were excellent for all drugs-the areas under curves were >0.9, 100% of sensitivity (S) and specificity (E) >80%. The genotypic method of RFLP oligotyping detected multidrug resistance with S of 100% and E of 93%. Conclusion. The results indicated that Alamar blue, MTT and RFLP methodologies are rapid and useful tools for characterizing multidrug resistance in M. tuberculosis, particularly for those patients with high risk of developing multidrug resistant tuberculosis.
Assuntos
Mycobacterium tuberculosis/isolamento & purificação , Tuberculose Resistente a Múltiplos Medicamentos/genética , Antituberculosos/uso terapêutico , Resistência a Múltiplos Medicamentos/genética , Genótipo , Humanos , Testes de Sensibilidade Microbiana , Mycobacterium tuberculosis/efeitos dos fármacos , Mycobacterium tuberculosis/genética , Fenótipo , Reação em Cadeia da Polimerase , Tuberculose Resistente a Múltiplos Medicamentos/diagnósticoRESUMO
OBJECTIVE: The present work evaluated a multi-antigen printing immunoassay (MAPIA) for the serological diagnosis of tuberculosis. MATERIALS AND METHODS: Sera were obtained from 66 patients with tuberculosis, verified clinically and bacteriologically and from 47 healthy individuals (control group). Sample sera were used for detection of antibodies against 3 enriched mixtures of proteins and 5 unique recombinant antigens. The antigens were presented in a solid matrix. Sensitivity, specificity and predictive values were evaluated and confirmed by a logistic regression analysis. A prevalence value was calculated and used for the selection of the best antigenic combination. RESULTS: The sensitivity and specificity values of individual antigens varied between 5-83% and 9-100%. The enriched mixtures values were more accurate than those obtained with the recombinant antigens. Combinations of several antigens improved the sensitivity values up to the 81% level. In most cases, specificity values of 57% or less were obtained. CONCLUSIONS: These results suggested that the multiantigenic test can be a useful screening tool, to be used in conjunction with the more definitive diagnostic tests.
Assuntos
Antígenos de Bactérias/imunologia , Mycobacterium tuberculosis/imunologia , Tuberculose/diagnóstico , Anticorpos Antibacterianos/sangue , Anticorpos Antibacterianos/imunologia , Antígenos de Bactérias/sangue , Ensaio de Imunoadsorção Enzimática , Humanos , Sensibilidade e Especificidade , Testes Sorológicos/métodos , Tuberculose/sangue , Tuberculose/imunologiaRESUMO
PURPOSE: The potential utility of circulating tumor cells (CTCs) as liquid biopsies is of great interest. We hypothesized that CTC capture using EpCAM based gating is feasible for most breast cancer subtypes. RESULTS: Cancer cells could be recovered from all intrinsic subtypes of breast cancer with IE/FACS, however, claudin-low cell lines showed very low capture rates compared to the four other groups (p = 0.03). IE/FACS detection of CTC mimic cells was time sensitive, emphasizing controlling for pre-analytic variables in CTC studies. Median fluorescent intensity for flow cytometry and RNA flow cell type characterization were highly correlated, predicting for CTC isolation across molecular subtypes. RNA-Seq of IE/FACS sorted single cell equivalents showed high correlation compared to bulk cell lines, and distinct gene expression signatures compared to PB. MATERIALS AND METHODS: Ten cell lines representing all major subtypes of breast cancer were spiked (as CTC mimics) into and recovered from peripheral blood (PB) using immunomagnetic enrichment followed by fluorescence-activated cell sorting (IE/FACS). Flow cytometry and RNA flow were used to quantify the expression of multiple breast cancer related markers of interest. Two different RNA-Seq technologies were used to analyze global gene expression of recovered sorted cells compared to bulk cell lines and PB. CONCLUSIONS: EpCAM based IE/FACS detected and captured a portion of spiked cells from each of the 10 cell lines representing all breast cancer subtypes, including basal-like but not claudin-low cancers. The assay allows for the isolation of high quality RNA suitable for accurate RNA-Seq of heterogeneous rare cell populations.
Assuntos
Antígenos de Neoplasias/genética , Biomarcadores Tumorais/genética , Neoplasias da Mama/genética , Moléculas de Adesão Celular/genética , Claudinas/genética , Citometria de Fluxo , Perfilação da Expressão Gênica , Separação Imunomagnética , Células Neoplásicas Circulantes/metabolismo , RNA Neoplásico/genética , Antígenos de Neoplasias/metabolismo , Biomarcadores Tumorais/metabolismo , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Moléculas de Adesão Celular/metabolismo , Claudinas/metabolismo , Molécula de Adesão da Célula Epitelial , Estudos de Viabilidade , Feminino , Perfilação da Expressão Gênica/métodos , Regulação Neoplásica da Expressão Gênica , Humanos , Células MCF-7 , Células Neoplásicas Circulantes/patologia , Fenótipo , Análise de Sequência de RNA , Fatores de TempoRESUMO
Mutations at position 306 of embB (embB306) have been proposed as a marker for ethambutol resistance in Mycobacterium tuberculosis; however, recent reports of embB306 mutations in ethambutol-susceptible isolates caused us to question the biological role of this mutation. We tested 1,020 clinical M. tuberculosis isolates with different drug susceptibility patterns and of different geographical origins for associations between embB306 mutations, drug resistance patterns, and major genetic group. One hundred isolates (10%) contained a mutation in embB306; however, only 55 of these mutants were ethambutol resistant. Mutations in embB306 could not be uniquely associated with any particular type of drug resistance and were found in all three major genetic groups. A striking association was observed between these mutations and resistance to any drug (P < 0.001), and the association between embB306 mutations and resistance to increasing numbers of drugs was highly significant (P < 0.001 for trend). We examined the association between embB306 mutations and IS6110 clustering (as a proxy for transmission) among all drug-resistant isolates. Mutations in embB306 were significantly associated with clustering by univariate analysis (odds ratio, 2.44; P = 0.004). In a multivariate model that also included mutations in katG315, katG463, gyrA95, and kasA269, only mutations in embB306 (odds ratio, 2.14; P = 0.008) and katG315 (odds ratio, 1.99; P = 0.015) were found to be independently associated with clustering. In conclusion, embB306 mutations do not cause classical ethambutol resistance but may predispose M. tuberculosis isolates to the development of resistance to increasing numbers of antibiotics and may increase the ability of drug-resistant isolates to be transmitted between subjects.
Assuntos
Antituberculosos/farmacologia , Etambutol/farmacologia , Mycobacterium tuberculosis/efeitos dos fármacos , Mycobacterium tuberculosis/genética , Sequência de Bases , Análise por Conglomerados , DNA Bacteriano/genética , Farmacorresistência Bacteriana , Genes Bacterianos/genética , Testes de Sensibilidade Microbiana , Dados de Sequência Molecular , Família Multigênica , Análise Multivariada , Mutação/genética , Mutação/fisiologia , FilogeniaRESUMO
Introducción. La dificultad en el diagnóstico temprano y oportuno de la susceptibilidad a los medicamentos de Mycobacterium tuberculosis hace necesario el diseño y la evaluación de nuevas técnicas que superen la efectividad, reduzcan el costo y el tiempo que toman los métodos tradicionales. Objetivo. Evaluar y comparar dos metodologías fenotípicas y una genotípica, útiles en la determinación rápida de susceptibilidad de M. tuberculosis, teniendo el método de las proporciones múltiples como referencia. Materiales y métodos. Se incluyeron 21 cepas de M. tuberculosis para la evaluación de las metodologías fenotípicas de oxidación y reducción de Alamar azul (Maba) y el bromuro de 3-(4-5-dimetiletiazol-2-il)-2,5-difenil tetrazolio (MTT o Tema), frente a estreptomicina, isoniacida, rifampicina y etambutol. Mediante análisis ROC (receiver operative characteristic curves) se determinó el desempeño de las pruebas y se determinaron los valores pronósticos y el punto de corte para cada antibiótico. Además, mediante tablas de contingencia se determinó el desempeño y los valores predictivos de la metodología genotípica de PCR e hibridación reversa o rifoligotyping, versión 3, en la determinación de las cepas multirresistentes. Resultados. Los perfiles de susceptibilidad por las pruebas colorimétricas se obtuvieron a los 7 días, con valores de área bajo la curva menores de 0,9, sensibilidad de 100 por ciento y especificidad mayor de 80 por ciento. La metodología de rifoligotyping resultó eficaz en la detección de mutirresistencia, con sensibilidad de 100 por ciento y especificidad de 93 por ciento. Conclusión. Con los resultados obtenidos consideramos las pruebas Maba, Tema y rifoligotyping como alternativas rápidas y eficaces en la detección de farmacorresistencia de M. tuberculosis, aplicables a pacientes con alto riesgo de desarrollar tuberculosis multirresistente
Assuntos
Mycobacterium tuberculosis , Resistência a Múltiplos Medicamentos , Testes de Sensibilidade Microbiana/métodos , Resistência Microbiana a MedicamentosRESUMO
Introducción. La heterogeneidad en el patrón de reconocimiento antigénico observado en los enfermos infectados con Mycobacterium tuberculosis hace evidente la necesidad de contar con una técnica rápida y accesible para el diagnóstico de la enfermedad. La disponibilidad de pruebas que empleen diferentes antígenos podría ser de utilidad para aumentar la sensibilidad de la detección.Objetivo. Evaluar el uso de una prueba multiantigénica (Mapia) de fácil manejo y evaluación visual en el diagnóstico serológico de la tuberculosis. Metodología. Se estudiaron 66 sueros de pacientes con enfermedad tuberculosa comprobada y 47 sueros de individuos no tuberculosos, y se detectó la presencia de anticuerpos para 8 antígenos: 3 mezclas enriquecidas en antígenos y 5 antígenos recombinantes, incluidos en una matriz sólida cuya lectura se realizó cualitativamente. Los antígenos fueron evaluados por sus características de sensibilidad, especificidad y valores predictivos, confirmados mediante análisis de regresión logística del cual se obtuvo la razón de prevalencia utilizada para la selección de la combinación antigénica mas adecuada. Resultados. Los valores de sensibilidad y especificidad de los antígenos individuales variaron entre 5 por ciento y 83 por ciento y 9 por ciento y 100 por ciento, respectivamente; los valores de las mezclas enriquecidas fueron mejores que los valores presentados por los antígenos recombinantes. La combinación de varios antígenos mejoró notablemente los valores de sensibilidad hasta 81 por ciento, pero en la mayoría de los casos se obtuvieron valores de especificidad menores al 57 por ciento
Assuntos
Antígenos , Mycobacterium tuberculosis , Testes Sorológicos , Tuberculose/diagnóstico , SorotipagemRESUMO
Se detectó la presencia de autoanticuerpos contra la mucosa gástrica en pacientes con enfermedad gastroduodenal e infectados con Helicobacter pylori. Métodos: se estudiaron 39 pacientes, se tomaron biopsias gástricas y suero. Los anticuerpos IgG anti H. pylori se detectaron por la técnica de ELISA. Para la detección de anticuerpos antigástricos se utilizaron técnicas de inmunohistoquímica. Resultados: se detectó la bacteria en el 97,5 por ciento de los casos. Los anticuerpos contra la mucosa gástrica se encontraron en el 12,8 por ciento de los pacientes. Se hallaron dos patrones: a) autoanticuerpos contras las células parietales, b) autoanticuerpos contra la membrana apical del epitelio glandular. Conclusión: se evidenció la presencia de autoanticuerpos contra la mucosa gástrica en pacientes con enfermedad gastroduodenal, infectados con Helicobacter pylori. La presencia de autoanticuerpos puede estar involucrada en el desarrollo de la in.amación y posterior atro.a de la mucosa